Insulin degludec/insulin aspart produces a dose‐proportional glucose‐lowering effect in subjects with type 1 diabetes mellitus

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 659-664

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stem cell-based therapy for the treatment of Type 1 diabetes mellitus

By Krishna K Ananda   Rao G Venkateshwara   Rao KRS Sambasiva  

Regenerative Medicine, Vol. 2, Iss. 2, 2007-03 ,pp. : 171-177

Future Medicine

Access to resources Recommend Favorite

The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis

By Currie Craig J.   Poole Chris D.   Tetlow Tony   Holmes Paul   McEwan Phil  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 33-39

Informa Healthcare

Access to resources Recommend Favorite

The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis

By Poole Chris D.   Tetlow Tony   McEwan Phil   Holmes Paul   Currie Craig J.  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 41-48

Informa Healthcare

Access to resources Recommend Favorite

Dual‐hormone treatment with insulin and glucagon in patients with type 1 diabetes

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 31, Iss. 7, 2015-10 ,pp. : 672-679

John Wiley & Sons Inc

Access to resources Recommend Favorite